Developing a vaccine to improve flu protection in older adults.
TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS.
['FUNDING_OTHER'] · TENDEL THERAPIES INC. · NIH-10933286
This study is testing a new vaccine booster called BiTar-s3 to help older adults build a stronger defense against the flu by improving their immune response to different strains of the virus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TENDEL THERAPIES INC. (nih funded) |
| Locations | 1 site (KENSINGTON, UNITED STATES) |
| Trial ID | NIH-10933286 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new vaccine adjuvant called BiTar-s3, which aims to enhance the immune response against influenza by targeting specific parts of the virus that are common across various strains. The project involves constructing immunogens that are combined with the BiTar-s3 adjuvant and testing their safety and effectiveness in animal models, including mice and aged rhesus macaques. By improving the ability to generate neutralizing antibodies against the flu, this research seeks to provide better protection for older adults who are at higher risk of severe influenza complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those who are at increased risk for influenza complications.
Not a fit: Patients who are not older adults or those who have contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective flu vaccine that provides longer-lasting immunity for older adults.
How similar studies have performed: Other research has shown promise in using adjuvants to enhance vaccine responses, suggesting that this approach could be effective.
Where this research is happening
KENSINGTON, UNITED STATES
- TENDEL THERAPIES INC. — KENSINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINGLETON, KENTNER — TENDEL THERAPIES INC.
- Study coordinator: SINGLETON, KENTNER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.